2185 — Shanghai Bio-heart Biological Technology Co Share Price
- HK$587.89m
- HK$402.61m
- 12
- 31
- 59
- 22
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 0.84 | ||
Price to Tang. Book | 1.46 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | n/a | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -12.92% | ||
Return on Equity | -12.48% | ||
Operating Margin | n/a |
Financial Summary
Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | CNYm | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Shanghai Bio-heart Biological Technology Co Ltd is a China-based company mainly engaged in the business of interventional instruments. The Company's main businesses are the development and production of interventional cardiovascular devices. The Company's main products comprise fully bioresorbable scaffolds (BRS) and renal denervation (RDN). The Company's products are mainly used to meet medical needs for the treatment of coronary, peripheral artery disease and hypertension. The Company's products are used in addressing the unmet medical needs of Chinese patients for the treatment of coronary artery diseases and the unmet medical needs of patients for the treatment of uncontrolled hypertension. The Company mainly conducts its businesses in the domestic market and overseas markets.
Directors
- Wang Li CHM (52)
- Yunqing Wang CFO (37)
- Tao Cai OTH (35)
- Bradley Hubbard OTH (63)
- Peili Wang OTH (38)
- Chenzhao Zhang OTH (38)
- Siu Ying Kwok SEC (37)
- Li Cai NED (38)
- Ji Chen NED (34)
- Jie Yin NED (46)
- Quan Zhou NED (45)
- Sheung Wai Chan NID (67)
- Chien Cheng Lin NID (51)
- Xubo Lu NID (41)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- July 18th, 2014
- Public Since
- December 23rd, 2021
- No. of Employees
- 63
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
Stock Exchange of Hong Kong Limited
- Shares in Issue
- 243,937,000

- Address
- Room 302, 3/F, Building 4, SHANGHAI, 2012201
- Web
- http://www.bio-heart.com
- Phone
- +86 2168798511
- Auditors
- Ernst & Young CPA
Upcoming Events for 2185
Shanghai Bio-heart Biological Technology Co Ltd Annual Shareholders Meeting
Similar to 2185
Acotec Scientific Holdings
Stock Exchange of Hong Kong Limited
Beijing Airdoc Technology Co
Stock Exchange of Hong Kong Limited
AK Medical Holdings
Stock Exchange of Hong Kong Limited
AMCO United Holding
Stock Exchange of Hong Kong Limited
Angelalign Technology
Stock Exchange of Hong Kong Limited
FAQ
As of Today at 19:35 UTC, shares in Shanghai Bio-heart Biological Technology Co are trading at HK$2.41. This share price information is delayed by 15 minutes.
Shares in Shanghai Bio-heart Biological Technology Co last closed at HK$2.41 and the price had moved by +23.59% over the past 365 days. In terms of relative price strength the Shanghai Bio-heart Biological Technology Co share price has outperformed the FTSE Developed Asia Pacific Index by +25% over the past year.
There is no consensus recommendation for this security.
Find out moreShanghai Bio-heart Biological Technology Co does not currently pay a dividend.
Shanghai Bio-heart Biological Technology Co does not currently pay a dividend.
Shanghai Bio-heart Biological Technology Co does not currently pay a dividend.
To buy shares in Shanghai Bio-heart Biological Technology Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of HK$2.41, shares in Shanghai Bio-heart Biological Technology Co had a market capitalisation of HK$587.89m.
Here are the trading details for Shanghai Bio-heart Biological Technology Co:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 2185
Based on an overall assessment of its quality, value and momentum Shanghai Bio-heart Biological Technology Co is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Shanghai Bio-heart Biological Technology Co. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +44.28%.
As of the last closing price of HK$2.41, shares in Shanghai Bio-heart Biological Technology Co were trading +31.19% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Shanghai Bio-heart Biological Technology Co PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$2.41.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Shanghai Bio-heart Biological Technology Co's management team is headed by:
- Wang Li - CHM
- Yunqing Wang - CFO
- Tao Cai - OTH
- Bradley Hubbard - OTH
- Peili Wang - OTH
- Chenzhao Zhang - OTH
- Siu Ying Kwok - SEC
- Li Cai - NED
- Ji Chen - NED
- Jie Yin - NED
- Quan Zhou - NED
- Sheung Wai Chan - NID
- Chien Cheng Lin - NID
- Xubo Lu - NID